Loading...

PE anti-mouse CD69 Antibody PE anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PE_083106
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
  • H1dot2F3_PE_083106
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104507 50 µg DKK725
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104508 200 µg DKK1741
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  2. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  3. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  4. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  5. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  6. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  7. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  8. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  9. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  10. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  11. Liu M, et al. 2022. Cells. 11: . PubMed
  12. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  13. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  14. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  15. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  16. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  17. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  18. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  19. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  20. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  21. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  22. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  23. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  24. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  27. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  28. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  29. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  30. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  31. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  32. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  33. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  34. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  35. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  36. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  37. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  38. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  39. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  40. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  41. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  42. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  43. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  44. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  45. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  46. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  47. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  48. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  49. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  50. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  51. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  52. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  53. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  54. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  55. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  56. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  57. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  58. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  59. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  60. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  61. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  62. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  63. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  64. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  65. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  66. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  67. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  68. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  69. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  70. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  71. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  72. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  73. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  74. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  75. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  76. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  77. Lopes N, et al. 2022. Elife. 11:. PubMed
  78. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  79. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  80. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  81. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  82. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  83. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  84. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  85. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  86. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  87. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  88. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  89. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  90. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  91. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  92. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  93. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  94. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  95. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  96. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  97. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  98. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  99. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  100. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  101. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  102. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  103. Liu M, et al. 2022. Cells. 11: . PubMed
  104. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  105. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  106. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  107. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  108. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  109. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  110. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  111. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  112. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  113. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  114. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  115. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  116. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  117. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  118. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  119. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  120. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  121. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  122. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  123. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  124. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  125. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  126. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  127. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  128. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  129. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  130. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  131. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  132. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  133. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  134. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  135. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  136. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  137. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  138. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  139. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  140. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  141. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  142. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  143. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  144. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  145. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  146. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  147. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  148. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  149. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  150. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  151. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  152. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  153. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  154. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  155. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  156. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  157. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  158. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  159. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  160. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  161. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  162. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  163. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  164. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  165. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  166. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  167. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  168. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  169. Lopes N, et al. 2022. Elife. 11:. PubMed
  170. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  171. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  172. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  173. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  174. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  175. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  176. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  177. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  178. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  179. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  180. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  181. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  182. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  183. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  184. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
RRID
AB_313110 (BioLegend Cat. No. 104507)
AB_313111 (BioLegend Cat. No. 104508)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 4    Revision Date: 04/18/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PE_083106
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
  • H1dot2F3_PE_083106
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes (6 hours) stained with H1.2F3 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104507 50 µg DKK725
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104508 200 µg DKK1741
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  2. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  3. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  4. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  5. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  6. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  7. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  8. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  9. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  10. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  11. Liu M, et al. 2022. Cells. 11: . PubMed
  12. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  13. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  14. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  15. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  16. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  17. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  18. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  19. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  20. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  21. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  22. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  23. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  24. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  25. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  26. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  27. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  28. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  29. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  30. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  31. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  32. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  33. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  34. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  35. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  36. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  37. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  38. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  39. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  40. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  41. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  42. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  43. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  44. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  45. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  46. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  47. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  48. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  49. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  50. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  51. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  52. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  53. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  54. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  55. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  56. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  57. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  58. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  59. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  60. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  61. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  62. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  63. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  64. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  65. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  66. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  67. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  68. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  69. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  70. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  71. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  72. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  73. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  74. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  75. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  76. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  77. Lopes N, et al. 2022. Elife. 11:. PubMed
  78. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  79. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  80. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  81. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  82. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  83. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  84. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  85. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  86. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  87. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  88. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  89. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  90. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  91. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  92. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  93. Yuan Z, et al. 2011. Vaccine. 29:6614. PubMed
  94. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  95. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  96. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  97. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  98. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  99. Huis In 't Veld LGM, et al. 2022. Cell Mol Life Sci. 79:231. PubMed
  100. Xie T, et al. 2022. Mol Med Rep. 25: . PubMed
  101. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  102. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  103. Liu M, et al. 2022. Cells. 11: . PubMed
  104. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  105. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  106. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  107. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  108. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  109. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  110. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  111. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  112. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  113. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  114. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  115. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  116. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  117. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  118. Mier-Aguilar C, et al. 2016. PLoS One. 11:e0168155. PubMed
  119. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  120. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  121. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  122. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  123. Kmieciak M, et al. 2011. Breast Cancer Res Treat. 126:385. PubMed
  124. Holan V, et al. 2010. J Immunol. 184:2124. PubMed
  125. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  126. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
  127. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  128. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  129. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  130. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  131. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  132. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  133. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  134. Huang Z, et al. 2012. J Immunol. 188:5867. PubMed
  135. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  136. Luo W, et al. 2022. Front Immunol. 13:816761. PubMed
  137. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  138. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  139. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  140. Suryawanshi RK, et al. 2021. Nat Commun. 12:6020. PubMed
  141. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  142. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  143. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  144. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  145. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  146. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  147. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  148. Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed
  149. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  150. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  151. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  152. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  153. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  154. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  155. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  156. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  157. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  158. Pascual-Pasto G, et al. 2022. J Immunother Cancer. 10:. PubMed
  159. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  160. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  161. Skadow M, et al. 2019. J Immunol. 203:370. PubMed
  162. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  163. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  164. Passos C, et al. 2014. Food Chem. 15:161. PubMed
  165. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  166. van Geffen C, et al. 2021. Front Immunol. 12:695933. PubMed
  167. Jang A, et al. 2015. Life Sci . 135: 138-146. PubMed
  168. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  169. Lopes N, et al. 2022. Elife. 11:. PubMed
  170. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  171. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  172. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  173. Amantini C, et al. 2017. Oncotarget. 8:90766. PubMed
  174. Demaria O, et al. 2022. Cell Rep Med. 3:100783. PubMed
  175. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  176. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  177. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  178. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  179. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  180. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  181. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  182. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  183. Tsai S, et al. 2018. Cell Metab. 28:922. PubMed
  184. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
RRID
AB_313110 (BioLegend Cat. No. 104507)
AB_313111 (BioLegend Cat. No. 104508)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 4    Revision Date: 04/18/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account